Protocol for the Examination of Specimens From Patients With Primary Malignant Tumors of the Heart

Protocol applies to primary malignant cardiac tumors. Hematolymphoid neoplasms are not included.

No AJCC/UICC TNM Staging System
Protocol web posting date: October 2009

Procedure
- Resection

Authors
Kelly J. Butnor, MD, FCAP*
   Department of Pathology and Laboratory Medicine, Fletcher Allen Health Care/University of Vermont, Burlington, Vermont
Mary Beth Beasley, MD, FCAP
   Department of Pathology, Mt. Sinai Medical Center, New York, New York
Robert J. McKenna, MD
   Department of Thoracic Surgery, Cedars-Sinai Medical Center, Los Angeles, California
Nader T. Okby, MD, FCAP
   Orange Pathology Associates, Orange Regional Medical Center, Middletown, New York
Victor L. Roggli, MD, FCAP
   Department of Pathology, Duke University Medical Center, Durham, North Carolina
Henry D. Tazelaar, MD, FCAP
   Department of Pathology and Laboratory Medicine, Mayo Clinic Scottsdale, Scottsdale, Arizona
William D. Travis, MD, FCAP
   Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York
Saul Suster, MD, FCAP
   Department of Pathology, The Medical College of Wisconsin, Milwaukee, Wisconsin
For the Members of the Cancer Committee, College of American Pathologists

* Denotes primary author

Previous lead contributor: M. Elizabeth Hammond, MD
© 2009 College of American Pathologists (CAP). All rights reserved.

The College does not permit reproduction of any substantial portion of these protocols without its written authorization. The College hereby authorizes use of these protocols by physicians and other health care providers in reporting on surgical specimens, in teaching, and in carrying out medical research for nonprofit purposes. This authorization does not extend to reproduction or other use of any substantial portion of these protocols for commercial purposes without the written consent of the College.

The CAP also authorizes physicians and other health care practitioners to make modified versions of the Protocols solely for their individual use in reporting on surgical specimens for individual patients, teaching, and carrying out medical research for non-profit purposes.

The CAP further authorizes the following uses by physicians and other health care practitioners, in reporting on surgical specimens for individual patients, in teaching, and in carrying out medical research for non-profit purposes: (1) **Dictation** from the original or modified protocols for the purposes of creating a text-based patient record on paper, or in a word processing document; (2) **Copying** from the original or modified protocols into a text-based patient record on paper, or in a word processing document; (3) The use of a **computerized system** for items (1) and (2), provided that the Protocol data is stored intact as a single text-based document, and is not stored as multiple discrete data fields.

Other than uses (1), (2), and (3) above, the CAP does not authorize any use of the Protocols in electronic medical records systems, pathology informatics systems, cancer registry computer systems, computerized databases, mappings between coding works, or any computerized system without a written license from CAP. Applications for such a license should be addressed to the SNOMED Terminology Solutions division of the CAP.

Any public dissemination of the original or modified Protocols is prohibited without a written license from the CAP.

The College of American Pathologists offers these protocols to assist pathologists in providing clinically useful and relevant information when reporting results of surgical specimen examinations of surgical specimens. The College regards the reporting elements in the “Surgical Pathology Cancer Case Summary” portion of the protocols as essential elements of the pathology report. However, the manner in which these elements are reported is at the discretion of each specific pathologist, taking into account clinician preferences, institutional policies, and individual practice.

The College developed these protocols as an educational tool to assist pathologists in the useful reporting of relevant information. It did not issue the protocols for use in litigation, reimbursement, or other contexts. Nevertheless, the College recognizes that the protocols might be used by hospitals, attorneys, payers, and others. Indeed, effective January 1, 2004, the Commission on Cancer of the American College of Surgeons mandated the use of the required data elements of the protocols as part of its Cancer Program Standards for Approved Cancer Programs. Therefore, it becomes even more important for pathologists to familiarize themselves with these documents. At the same time, the College cautions that use of the protocols other than for their intended educational purpose may involve additional considerations that are beyond the scope of this document.

The inclusion of a product name or service in a CAP publication should not be construed as an endorsement of such product or service, nor is failure to include the name of a product or service to be construed as disapproval.
CAP Heart Protocol Revision History

Version Code
The definition of the version code can be found at www.cap.org/cancerprotocols.

Version: Heart 3.0.0.0

Summary of Changes
No changes have been made since the October 2009 release.
Surgical Pathology Cancer Case Summary

Protocol web posting date: October 2009

HEART: Resection

Select a single response unless otherwise indicated.

Specimen
___ Atrium
___ Ventricle
___ Interventricular septum
___ Other (specify): ________________
___ Not specified

Procedure
___ Resection
___ Excisional biopsy
___ Other (specify): ________________
___ Not specified

Specimen Integrity
___ Intact
___ Disrupted
___ Indeterminate

Specimen Laterality
___ Right
___ Left
___ Other (specify): ________________
___ Not specified

Tumor Site (select all that apply)
___ Pericardium
___ Right ventricle
___ Left ventricle
___ Right atrium
___ Left atrium
___ Interventricular septum
___ Other (specify): ________________
___ Not specified

Tumor Size (Note A)
___ Not applicable
Greatest dimension: ___ cm
+ Additional dimensions: ___ x ___ cm
___ Cannot be determined (see Comment)
Histologic Type (Note B)
___ Angiosarcoma
___ Epithelioid hemangioendothelioma
___ Malignant pleomorphic fibrous histiocytoma (MFH)/Undifferentiated pleomorphic sarcoma
___ Fibrosarcoma
___ Myxoid fibrosarcoma
___ Rhabdomyosarcoma
___ Leiomyosarcoma
___ Osteosarcoma
___ Synovial sarcoma
___ Liposarcoma
___ Other (specify): ________________________

Histologic Grade (Note C)
___ Not applicable
___ Cannot be determined
___ Grade 1
___ Grade 2
___ Grade 3
___ Other (specify): ________________________

Tumor Extension (select all that apply)
___ Cannot be determined
___ No involvement of adjacent tissue(s)
___ Involvement of adjacent tissue(s) (specify): ________________________
___ Other organ involvement (specify): ________________________

Margins
___ Not applicable
___ Cannot be assessed
___ Negative for tumor
___ Involved by tumor
   Specify site(s), if known: ________________________

Treatment Effect
___ Not applicable
___ Cannot be determined
___ Not identified
___ Present (specify: ___% residual viable tumor)

Lymph-Vascular Invasion
___ Present
___ Not identified
___ Indeterminate

+ Additional Pathologic Findings (select all that apply)
+ ___ None identified
+ ___ Inflammation
+ ___ Other (specify): ________________________

+ Comment(s)
Explanatory Notes

A. Staging
The greatest diameter of the tumor in centimeters should be recorded. There is no published staging system for primary cardiac tumors.

B. Histologic Type
For consistency in reporting, the histologic classification published by the World Health Organization (WHO) for tumors of the heart is recommended.¹ The histologic types are listed in this protocol in the order they appear in the WHO classification. This protocol does not preclude the use of other systems of classification of histologic types.²

C. Histologic Grade
Pathologists should grade the tumor and indicate the grading system used. Most malignant tumors of the heart are sarcomas.³ Necrosis of groups of cells and mitotic rates of greater than 5 mitoses per 10 high-power fields have been associated with reduced survival.¹² Parameters of the grading system for sarcomas of the Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC) are shown below.⁴

Tumor Differentiation
Score 1: Sarcomas closely resembling normal adult mesenchymal tissue (eg, low-grade leiomyosarcoma)
Score 2: Sarcomas for which histologic typing is certain (eg, myxoid fibrosarcoma)
Score 3: Undifferentiated, angiosarcoma

Mitotic Count
Score 1: 0-9 mitoses per 10 HPF*
Score 2: 10-19 mitoses per 10 HPF
Score 3: ≥20 mitoses per 10 HPF

Tumor Necrosis
Score 0: No necrosis
Score 1: <50% tumor necrosis
Score 2: ≥50% tumor necrosis

Histologic Grade
Grade 1: Total score 2, 3
Grade 2: Total score 4, 5
Grade 3: Total score 6, 7, 8

* A high-power field (HPF) measure 0.1734 mm²
References


